Literature DB >> 23553022

[Metabolic and mitochondrial myopathies].

M Vorgerd1, M Deschauer.   

Abstract

Metabolic myopathies include a broad group of diseases involving inherited enzyme defects in the various metabolic pathways and skeletal musculature. They show an extensive phenotypic variability of symptoms and different ages of manifestation. Symptoms often included intolerance to duress or permanent paresis. Some forms of metabolic myopathy, in particular mitochondriopathy, are associated with multsystemic organ participation. The diagnostics must be adjusted to individual cases and carried out in stages. Primary investigations should include blood parameters (e.g. creatine kinase measurement, muscle load tests and determination of the acylcarnitine spectrum) and a second step includes muscle biopsy for histological and enzyme investigations and special molecular genetic tests although the causative enzyme defect cannot be clarified in every case. On the other hand by means of a thorough investigation it is particularly important in patients with load intolerance to differentiate between other causes, in particular psychosomatic diseases. If this is not done there is a danger of classifying the symptoms of a metabolic myopathy as a somatoform disorder. Therapy is mostly symptom-oriented as Pompe disease is the only one which can be treated with enzyme replacement therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23553022     DOI: 10.1007/s00393-012-1082-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  28 in total

Review 1.  The diagnosis of mitochondrial muscle disease.

Authors:  Robert W Taylor; Andrew M Schaefer; Martin J Barron; Robert McFarland; Douglass M Turnbull
Journal:  Neuromuscul Disord       Date:  2004-04       Impact factor: 4.296

2.  Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.

Authors:  Tina D Jeppesen; Marianne Schwartz; David B Olsen; Flemming Wibrand; Thomas Krag; Morten Dunø; Simon Hauerslev; John Vissing
Journal:  Brain       Date:  2006-06-30       Impact factor: 13.501

3.  Bezafibrate for an inborn mitochondrial beta-oxidation defect.

Authors:  Jean-Paul Bonnefont; Jean Bastin; Anthony Behin; Fatima Djouadi
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

4.  Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study.

Authors:  Matthias Vorgerd; Jochen Zange; Rudolf Kley; T Grehl; Anika Hüsing; Matthias Jäger; Klaus Müller; Rolf Schröder; Wilhelm Mortier; Klaus Fabian; Jean-Pierre Malin; Alwin Luttmann
Journal:  Arch Neurol       Date:  2002-01

5.  Analysis of spectrum and frequencies of mutations in McArdle disease. Identification of 13 novel mutations.

Authors:  M Deschauer; A Morgenroth; P R Joshi; D Gläser; P F Chinnery; J Aasly; H Schreiber; M Knape; S Zierz; M Vorgerd
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

Review 6.  Disorders of carnitine transport and the carnitine cycle.

Authors:  Nicola Longo; Cristina Amat di San Filippo; Marzia Pasquali
Journal:  Am J Med Genet C Semin Med Genet       Date:  2006-05-15       Impact factor: 3.908

7.  Clinical and genetic analysis of lipid storage myopathies.

Authors:  Aya Ohkuma; Satoru Noguchi; Hideo Sugie; May Christine V Malicdan; Tokiko Fukuda; Kunio Shimazu; Luis Carlos López; Michio Hirano; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

8.  Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity.

Authors:  S T Andersen; J Vissing
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-12       Impact factor: 10.154

9.  ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.

Authors:  Rikke K J Olsen; Simon E Olpin; Brage S Andresen; Zofia H Miedzybrodzka; Morteza Pourfarzam; Begoña Merinero; Frank E Frerman; Michael W Beresford; John C S Dean; Nanna Cornelius; Oluf Andersen; Anders Oldfors; Elisabeth Holme; Niels Gregersen; Douglass M Turnbull; Andrew A M Morris
Journal:  Brain       Date:  2007-06-20       Impact factor: 13.501

10.  Effect of vitamin B6 supplementation in McArdle's disease: a strategic case study.

Authors:  J Phoenix; P Hopkins; C Bartram; R J Beynon; R C Quinlivan; R H Edwards
Journal:  Neuromuscul Disord       Date:  1998-05       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.